Skip to the content
FSHD Europe

FSHD Europe

FSHD

  • Home
  • About Us
    • Member Organisations
    • Contact
    • Who we are…
      • Sheila Hawkins
      • Paola de Donato
  • News
    • Events
    • Stories
  • What is FSHD
  • FSHD European Patient Survey
    • Lay Report
    • Supporters
  • FSHD European Trial Network
    • What is it about?
    • Core Group of Experts
  • Research
    • Guidelines
    • Clinical trials
  • Governance
    • Policies
    • Financial Reports
    • Statutes
  • Links
Clinical trials News

Fulcrum Therapeutics® Announces Phase 3 Clinical Trial of Losmapimo (REACH)

March 3, 2022 By Bine Haase

https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeuticsr-announces-reach-phase-3-clinical-trial/?fbclid=IwAR2WpAYsthlB2it094PMDEGP9b671YY5pKh7vQSgU10IEc5vxzHqMIu5rj4

Post navigation

Previous PostPrevious FSHD European Trial Network (FSHD ETN) Newsletter 2 – January 2022
Next PostNext Update and News regarding the Patient Pharma Survey!
Proudly powered by WordPress | Theme: Popularis